Analysis of these samples by RT-PCR showed that PADI4 mRNA levels were significantly elevated in MS patients compared to the genetically related healthy controls (approx. 1.5-fold, Figure 6F). This evidence concerns the gene PADI4 and myeloid sarcoma.